The Economic Times
English EditionEnglish Editionहिन्दी
| 02 December, 2020, 05:22 AM IST | E-Paper
Search
+

    Expert Views

    Don't sell & run away, December may be better than November

    We have had extremely good volumes, over Rs 60,000 crore in a single day. I expect it to go even higher, says Deepak Shenoy.

    Wockhardt in talks with a number of vaccine manufacturers

    Manufacturing of vaccines is a big opportunity for Indian pharmaceutical industry, says Habil Khorakiwala. Wockhardt is in partmership with UK govt to manufacture Covid-19 vaccine .

    Two-wheeler industry showing 10% decline, mostly at entry level

    Bajaj Auto experienced double digit growth but as you move down the pyramid and ride to the entry level, it goes into a decline, says Rakesh Sharma.

    How Samir Arora & Raamdeo Agrawal learnt from their mistakes

    Market gurus on biggest learnings from the mistakes they have made.

    Sustainable demand in auto will start picking up in Q4

    Tractors and passenger vehicles lead retail momentum in auto. Commercial vehicles are recovering fast but still may be flattish to down on a year-on-year basis, says Jay Kale.

    Look beyond largecaps, dig deeper in pharma & IT

    From July-August, we have seen a steady re-rating in the small and midcaps which should accelerate into next year, says Hiren Ved.

    Find verified Mutual Funds Consultants near your location

    BULL'S EYE

    What markets can expect in December

    In terms of events, December could be a much more subdued and docile month with no significant events or triggers on the horizon, says Kunj Bansal.

    What to buy as the rally gets broader

    FII money will target the large cap stocks and that will make the index move up once again, says Sudip Bandyopadhyay.

    3 cements stocks to buy cutting across market caps

    We prefer UltraTech as a large cap top pick followed by JK Cement in the midcap space and ACC as a value pick, says Siddhartha Khemka.

    Start accumulating Reliance if it falls below Rs 2,000

    Any good correction will be an opportunity to buy RIL from an investment perspective, says Siddhartha Khemka.

    Pharma, chemical stocks could consolidate over next 3 months

    Pharma, chemical stocks could consolidate over next 3 months

    Longer term, pharma and chemicals is a very structural story underlying these businesses and probably they will do very well, says Pankaj Murarka.

    Bank stocks are nearing overbought territory

    Bank stocks are nearing overbought territory

    ‘There is a higher chance that the Nifty would remain more or less in the range 13,200 to 12,800’

    Worst is over! By Q4, 2.5% positive growth likely: Kaushik Das

    Worst is over! By Q4, 2.5% positive growth likely: Kaushik Das

    In Q3, we could end up with minus 1.5% and if we are lucky we can even get a positive number.

    Positive GDP number not likely before next financial year

    Positive GDP number not likely before next financial year

    I am not confident that incrementally Q3 numbers will be proportionately better. A positive number can be expected only in the next financial year, says Siddhartha Sanyal

    DIIs may now divert their money from largecaps to midcaps and smallcaps: Nirmal Jain

    DIIs may now divert their money from largecaps to midcaps and smallcaps: Nirmal Jain

    The low interest rate has a big role in reviving growth and I only hope that RBI and the government maintain benign liquidity and in a falling interest rates scenario,says the Chairman & CEO, IIFL Finance.

    IGL may have to hike prices marginally after PNGRB directive

    IGL may have to hike prices marginally after PNGRB directive

    The directive has implications from an investment standpoint as the incumbent CGDs will have to spend more aggressively to protect their market share against whatever third parties or OMCs might be looking to grab, says Probal Sen.

    Load More...
    The Economic Times
    BACK TO TOP